SCHEMBL6206979

SCHEMBL6206979

COC(=O)C(Cc1ccc(C)c(OC)c1)C(=O)OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 2/20 0.58
TAS1R3 Q7RTX0 1/20 0.48
TAS1R1 Q7RTX1 1/20 0.48
PTPRB P23467 1/20 0.48
PPARG P37231 4/20 0.46
PPARD Q03181 3/20 0.46
PPARA Q07869 3/20 0.46
ALDH1A1 P00352 3/20 0.44
FOS P01100 1/20 0.44
TTR P02766 1/20 0.44
JUN P05412 1/20 0.44
NR3C1 P04150 1/20 0.44
HSD17B1 P14061 1/20 0.44
HSD17B2 P37059 1/20 0.44
PKM P14618 1/20 0.43
ALOX15 P16050 1/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 1/20 0.43
MMP1 P03956 1/20 0.42
ADRB2 P07550 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6171836 0.87 LDHA (0.76) LDHAALDH1A1FOSTTRJUN
SCHEMBL30958039 0.85 ALDH1A1 (0.61) LDHATAS1R3TAS1R1ALDH1A1FOS
SCHEMBL5148707 0.85 ALDH1A1 (0.61) LDHATAS1R3TAS1R1ALDH1A1FOS
SCHEMBL934471 0.84 FOS (0.64) LDHAALDH1A1FOSTTRJUN
Hydrochloric Acid SCHEMBL5148704 0.84 ALDH1A1 (0.63) LDHATAS1R3TAS1R1ALDH1A1FOS
SCHEMBL933495 0.81 HSD17B2 (0.56) LDHAALDH1A1FOSTTRJUN
SCHEMBL9244545 0.81 LDHA (0.82) LDHAPPARGPPARDPPARAALDH1A1
SCHEMBL6378609 0.81 ALOX15 (0.64) LDHAALOX15CYP3A4
SCHEMBL9438086 0.80 LDHA (0.69) LDHAALDH1A1PKMALOX15
SCHEMBL5150577 0.79 TAS1R3 (0.50) LDHATAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0966446-B1 BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE WARNER LAMBERT CO (US) 2005-10-19 EP disclosed
US-6528535-B2 Anticancer agents; restenosis WARNER-LAMBERT COMPANY 2003-03-04 US disclosed
US-20020006936-A1 Bicyclic inhibitors of protein farnesyl transferase BIKKER JACK (US) 2002-01-17 US disclosed
US-6265422-B1 ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS WARNER-LAMBERT COMPANY 2001-07-24 US disclosed
US-6133303-A VARIOUS INDENE DERIVATIVES, WITH THE EXCEPTION OF 5-(2-IMIDAZOLE-1-YL-ETHOXY)INDAN-1-ONE; TREATING CANCER AND TREATING OR PREVENTING RESTENOSIS OR ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 2000-10-17 US disclosed
EP-0966446-A1 BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE WARNER-LAMBERT COMPANY (US) 1999-12-29 EP disclosed
WO-1998034921-A1 BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE WARNER-LAMBERT COMPANY (US) 1998-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006936-A1 Bicyclic inhibitors of protein farnesyl transferase FNTA, FNTB, SREBF1 LDHA 4632/4885TAS1R3 4370/4885TAS1R1 4247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.